https://www.macrotrends.net/stocks/charts/ALPMY/astellas-pharma/gross-profit
Astellas Pharma Gross Profit 2012-2025 | ALPMY | MacroTrends
Astellas Pharma annual/quarterly gross profit history and growth rate from 2012 to 2025. Gross profit can be defined as the profit a company makes after...
astellas pharmagross profit20122025alpmy
https://mentalhealthfirstaid.org/case-study/astellas-pharma-us/
MHFA Case Study: Astellas Pharma US
Nov 29, 2025 - Pharmaceutical giant Astellas Pharma has trained approximately 40 employees in Mental Health First Aid in the past year.
case studyastellas pharmamhfaus
https://www.nasdaq.com/market-activity/stocks/alpmf
Astellas Pharma Inc. (ALPMF) Stock Price, Quote, News & History | Nasdaq
Discover real-time Astellas Pharma Inc. (ALPMF) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay...
astellas pharma incstock price quotenews historynasdaq
https://www.nasdaq.com/market-activity/stocks/alpmy/historical-nocp
Astellas Pharma Inc. ADR (ALPMY) Historical NOCP | Nasdaq
Get the latest insights on Astellas Pharma Inc. ADR (ALPMY) historical NOCP to help you in your trading and investing decisions.
astellas pharma inchistorical nocpadralpmynasdaq
https://www.macrotrends.net/stocks/charts/ALPMY/astellas-pharma/gross-margin
Astellas Pharma Gross Margin 2012-2025 | ALPMY | MacroTrends
Current and historical gross margin for Astellas Pharma (ALPMY) over the last 10 years. The current gross profit margin for Astellas Pharma as of December 31,...
astellas pharmagross margin20122025alpmy
https://www.macrotrends.net/stocks/charts/ALPMY/astellas-pharma/price-book
Astellas Pharma Price to Book Ratio 2012-2025 | ALPMY | MacroTrends
price to book ratioastellas pharma20122025alpmy
https://www.biospace.com/ajinomoto-and-astellas-pharma-inc-jointly-file-application-seeking-additional-approval-for-combination-therapy-of-fastic-starsis-tablets
Ajinomoto And Astellas Pharma Inc. Jointly File Application Seeking Additional Approval For...
astellas pharma incjointly file
https://www.macrotrends.net/stocks/charts/ALPMY/astellas-pharma/total-share-holder-equity
Astellas Pharma Share Holder Equity 2012-2025 | ALPMY | MacroTrends
share holder equityastellas pharma20122025alpmy
https://theorg.com/org/astellas-pharma?person=claus-zieler
Astellas Pharma | The Org
Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on...
astellas pharma
https://capital.com/en-int/markets/shares/astellas-pharma-inc-share-price
Astellas Pharma Inc. (4503) Stock Price Quote Today & Current Price Chart | Capital.com
astellas pharma incstock price quote
https://www.verizon.com/business/resources/customer-success-stories/astellas-pharma/
Astellas Pharma Case Study | Verizon Enterprise Solutions
See how Astellas Pharma Inc. found a competitive edge in the cloud in this case study. By working with Verizon Enterprise Solutions, Astellas was able to...
pharma case studyastellasverizonenterprisesolutions
https://www.macrotrends.net/stocks/charts/ALPMY/astellas-pharma/ebitda-margin
Astellas Pharma EBITDA Margin 2012-2025 | ALPMY | MacroTrends
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Astellas Pharma (ALPMY) over the last 10 years. The...
astellas pharmaebitda margin20122025alpmy
https://www.biospace.com/astellas-pharma-inc-appoints-new-u-s-research-and-development-head
Astellas Pharma Inc. Appoints New U.S. Research & Development Head - BioSpace
astellas pharma incresearch developmentappointsnew
https://www.nasdaq.com/market-activity/stocks/alpmy
Astellas Pharma Inc. ADR (ALPMY) Stock Price, Quote, News & History | Nasdaq
Discover real-time Astellas Pharma Inc. ADR (ALPMY) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions....
astellas pharma incstock price quotenews historyadralpmy
https://www.pymnts.com/cpi-posts/astellas-pharma-acquires-iveric-bio-for-5-9-billion/
Astellas Pharma Acquires Iveric Bio For $5.9 Billion | PYMNTS.com
May 1, 2023 - Astellas Pharma Inc has reached an agreement to acquire Iveric Bio Inc for $5.9 billion in cash, valuing each share at $40.00. Astellas has made a deal with...
astellas pharma5 9acquiresbio
https://theorg.com/org/astellas-pharma?person=tadaaki-taniguchi
Astellas Pharma | The Org
Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on...
astellas pharma
https://www.companiesmarketcap.com/hkd/astellas-pharma/marketcap/
Astellas Pharma (4503.T) - Market capitalization
As of May 2026 Astellas Pharma has a market cap of HK$205.43 Billion. This makes Astellas Pharma the world's 922th most valuable company according to our data.
astellas pharma4503marketcapitalization
https://www.verizon.com/business/en-au/resources/customer-success-stories/astellas-pharma/
Astellas Pharma Case Study | Verizon Enterprise Solutions
See how Astellas Pharma Inc. found a competitive edge in the cloud in this case study. By working with Verizon Enterprise Solutions, Astellas was able to...
pharma case studyastellasverizonenterprisesolutions
https://www.nasdaq.com/market-activity/stocks/alpmy/revenue-eps
Astellas Pharma Inc. ADR (ALPMY) Revenue EPS | Nasdaq
Find the latest Revenue Earnings Per Share data for Astellas Pharma Inc. ADR (ALPMY) at Nasdaq.com.
astellas pharma incadralpmyrevenueeps
https://www.prnewswire.com/news/astellas-pharma-europe-ltd/
Astellas Pharma Europe Ltd News and Press Releases | PR Newswire
news and press releasesastellas pharmaeuropeltdnewswire
https://www.macrotrends.net/stocks/charts/ALPMY/astellas-pharma/price-fcf
Astellas Pharma Price to Free Cash Flow Ratio 2012-2025 | ALPMY | MacroTrends
Historical price to free cash flow ratio values for Astellas Pharma (ALPMY) since 2012.
free cash flowastellas pharma
https://theorg.com/org/astellas-pharma?person=shinsuke-oba
Astellas Pharma | The Org
Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on...
astellas pharma
https://www.biospace.com/astellas-pharma-inc-receives-fda-approval-for-use-of-prograf-r-tacrolimus-in-conjunction-with-mycophenolate-mofetil-mmf-in-kidney-transplant-rec
Astellas Pharma Inc. Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With...
https://www.epo.org/en/boards-of-appeal/decisions/t230679eu1
T 0679/23 (anti-CLD18.2 combination therapy/ASTELLAS PHARMA) of 14.02.2025
https://www.biospace.com/astellas-pharma-us-highlights-progress-to-advance-care-of-patients-with-genitourinary-cancers-at-american-society-of-clinical-oncology-gu-annual-meeti
Astellas Pharma US Highlights Progress to Advance Care of Patients with Genitourinary Cancers at...
astellas pharma us
https://www.biospace.com/b-cyclenium-pharma-b-announces-drug-discovery-collaboration-agreement-with-astellas-pharma-inc
Cyclenium Pharma Announces Drug Discovery Collaboration Agreement With Astellas Pharma Inc. -...
drug discoverycollaboration agreementpharmaannouncesastellas
https://www.prnewswire.co.uk/news-releases/global-overactive-bladder-market-report-2017-2027-astellas-pharma-leads-industry-sponsors-with-the-674465293.html
Global Overactive Bladder Market Report 2017-2027: Astellas Pharma Leads Industry Sponsors with the...
/PRNewswire/ -- The "Market Spotlight: Overactive Bladder" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...